- Home
- NNY vs CVRX Comparison
NNY vs CVRX Comparison
Compare NNY & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- CVRX
- Stock Information
- Founded
- NNY 1987
- CVRX 2000
- Country
- NNY United States
- CVRX United States
- Employees
- NNY N/A
- CVRX N/A
- Industry
- NNY Investment Managers
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NNY Finance
- CVRX Health Care
- Exchange
- NNY Nasdaq
- CVRX Nasdaq
- Market Cap
- NNY 155.1M
- CVRX 174.4M
- IPO Year
- NNY N/A
- CVRX 2021
- Fundamental
- Price
- NNY $8.05
- CVRX $5.89
- Analyst Decision
- NNY
- CVRX Buy
- Analyst Count
- NNY 0
- CVRX 7
- Target Price
- NNY N/A
- CVRX $14.50
- AVG Volume (30 Days)
- NNY 50.9K
- CVRX 232.7K
- Earning Date
- NNY 01-01-0001
- CVRX 07-28-2025
- Dividend Yield
- NNY 4.04%
- CVRX N/A
- EPS Growth
- NNY N/A
- CVRX N/A
- EPS
- NNY N/A
- CVRX N/A
- Revenue
- NNY N/A
- CVRX $52,870,000.00
- Revenue This Year
- NNY N/A
- CVRX $11.53
- Revenue Next Year
- NNY N/A
- CVRX $18.61
- P/E Ratio
- NNY N/A
- CVRX N/A
- Revenue Growth
- NNY N/A
- CVRX 25.62
- 52 Week Low
- NNY $7.58
- CVRX $4.30
- 52 Week High
- NNY $8.87
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- NNY 37.34
- CVRX 41.15
- Support Level
- NNY $7.77
- CVRX $5.54
- Resistance Level
- NNY $8.11
- CVRX $5.96
- Average True Range (ATR)
- NNY 0.21
- CVRX 0.40
- MACD
- NNY -0.01
- CVRX -0.03
- Stochastic Oscillator
- NNY 27.45
- CVRX 21.99
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.